Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 8.7% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares were down 8.7% during trading on Friday . The company traded as low as $0.31 and last traded at $0.34. Approximately 46,071,262 shares were traded during trading, an increase of 52% from the average daily volume of 30,282,193 shares. The stock had previously closed at $0.37.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research note on Monday. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm has a market capitalization of $63.99 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a 50-day simple moving average of $0.22 and a two-hundred day simple moving average of $0.41. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. As a group, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.